Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid-Free Analgesia In Intensive Care Unit (OFICU)
2024-517770-14-00Phase 4Authorised
- Sponsor
- CHU Nîmes
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remifentanil in pain and mechanical ventilation (2 arms), sponsored by CHU Nîmes. Primary endpoint: Daily consumption of remifentanil between 24 and 48 hours after randomisation. Planned start May 2023; status: authorised.
02
Drugs
remifentanil
03
Conditions
painmechanical ventilation
Beyond the preview
Go deeper on 2024-517770-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517770-14-00.